Deal Watch: Merger Addresses Problems Of Both Aegerion, QLT
Convinced on safety, Shire buys Phase III-ready IBD candidate from Pfizer. Teva looks ahead to its acquisition of Allergan's generic portfolios by divesting ANDAs through two deals, while ending a stem cell collaboration with Mesoblast.
You may also be interested in...
European firms Amryt and Evotec have signed agreements to acquire two companies based across the Atlantic – Aegerion and Just Biotherapeutics, respectively.
Now studying stem-cell candidate MPC-150-IM in two 600-patient Phase III trials in advanced heart failure, the partners could complete the Phase III program more quickly and less expensively.
In drug development, the tiniest of targets sometimes prove windows of huge opportunity. For chronic pain start-up Afferent Pharmaceuticals Inc., a single receptor subfamily may hold the key to unlocking novel treatments for that tough-to-alleviate disorder and a remarkable number of other diseases.